CA2626698A1 - Methode de traitement d'une diarrhee associee a clostridium difficile - Google Patents

Methode de traitement d'une diarrhee associee a clostridium difficile Download PDF

Info

Publication number
CA2626698A1
CA2626698A1 CA002626698A CA2626698A CA2626698A1 CA 2626698 A1 CA2626698 A1 CA 2626698A1 CA 002626698 A CA002626698 A CA 002626698A CA 2626698 A CA2626698 A CA 2626698A CA 2626698 A1 CA2626698 A1 CA 2626698A1
Authority
CA
Canada
Prior art keywords
mixture
weight
mcc
compound
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002626698A
Other languages
English (en)
Other versions
CA2626698C (fr
Inventor
Pamela Sears
Youe-Kong Shue
Starr Louise Miller-Shangle
Robert Brian Walsh
Farah Babakhani
Yu-Hung Chiu
Alex Romero
Sherwood Gorbach
Thomas John Louie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Merck Sharp and Dohme LLC
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC, Optimer Pharmaceuticals LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2626698A1 publication Critical patent/CA2626698A1/fr
Application granted granted Critical
Publication of CA2626698C publication Critical patent/CA2626698C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2626698A 2005-10-21 2006-10-23 Methode de traitement d'une diarrhee associee a clostridium difficile Expired - Fee Related CA2626698C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12
PCT/US2006/041436 WO2007048059A2 (fr) 2005-10-21 2006-10-23 Méthode de traitement d'une diarrhée associée à clostridium difficile

Publications (2)

Publication Number Publication Date
CA2626698A1 true CA2626698A1 (fr) 2007-04-26
CA2626698C CA2626698C (fr) 2015-12-01

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2626698A Expired - Fee Related CA2626698C (fr) 2005-10-21 2006-10-23 Methode de traitement d'une diarrhee associee a clostridium difficile

Country Status (8)

Country Link
EP (1) EP1940417A4 (fr)
JP (1) JP2009512691A (fr)
KR (1) KR101399621B1 (fr)
CN (2) CN102503994A (fr)
AU (1) AU2006304868B2 (fr)
CA (1) CA2626698C (fr)
HK (1) HK1126410A1 (fr)
WO (1) WO2007048059A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
EP4242295A3 (fr) * 2018-06-07 2023-10-18 Artugen Therapeutics Ltd. Souche de b. amyloliquefaciens et utilisation thérapeutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production
JP5734545B2 (ja) * 2004-05-14 2015-06-17 オプティマー ファーマシューティカルズ、インコーポレイテッド 抗生物質の使用に関連する疾患の治療
MX340742B (es) * 2005-01-31 2016-07-21 Merck Sharp & Dohme Compuestos macrociclicos de 18 miembros y analogos de los mismos.

Also Published As

Publication number Publication date
CN101340919A (zh) 2009-01-07
WO2007048059A3 (fr) 2007-05-31
KR20080064177A (ko) 2008-07-08
JP2009512691A (ja) 2009-03-26
EP1940417A2 (fr) 2008-07-09
HK1126410A1 (en) 2009-09-04
AU2006304868A1 (en) 2007-04-26
EP1940417A4 (fr) 2010-07-07
CA2626698C (fr) 2015-12-01
AU2006304868B2 (en) 2013-02-21
CN102503994A (zh) 2012-06-20
KR101399621B1 (ko) 2014-06-18
CN101340919B (zh) 2011-12-07
WO2007048059A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
CA2626698C (fr) Methode de traitement d'une diarrhee associee a clostridium difficile
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
Eykyn et al. Metronidazole and anaerobic sepsis.
EP2305244B1 (fr) Traitement de maladies consecutives a un traitement antibiotique
CN102614207A (zh) 18元环大环化合物及其类似物
Bäckström et al. Effect of ceftobiprole on the normal human intestinal microflora
CN102405223A (zh) 利福霉素衍生物
US20120258980A1 (en) Antibacterial Agent for Drug-Resistant Bacteria, Method for Screening for Same, and Use of Same
Citron et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
KR0145553B1 (ko) 클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물
Naber et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections
Mitscher Coevolution: mankind and microbes
Yanagihara et al. Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118
WO2012050826A1 (fr) Procédés de traitement d'infections par clostridium difficile
CN111249264A (zh) 没食子酸在逆转猪链球菌对抗生素耐药性中的用途
JP6130248B2 (ja) 新規化合物キノフラシン類、その製造方法、及びその用途、並びに新規微生物
CA2538842C (fr) Composition de glycopeptide avec une activite antibiotique
CN105919995B (zh) 阿扎霉素f在制备治疗特应性皮炎药物中的应用
US20240066022A1 (en) Diiodohydroxyquinoline for the treatment of clostridium difficile infection
EP2531223A2 (fr) Nouveaux procédés et nouvelles utilités
CN115710167A (zh) 两个二苯醚化合物及其制备方法和在制备抗菌药物中的应用
CN111249296A (zh) 一种抗真菌的药物组合物及互动抗真菌活性测定方法
JP2010059057A (ja) 蛋白質毒素の分泌阻害剤
JP2009073791A (ja) 新規生理活性物質ｒｋｇｓ−ａ２２１５ａ

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171023